According to the U.S. National Institutes of Health which helped fund the study, the vaccine regime was safe and reduced by 31% the chance of infection with the AIDS causing human immunodeficiency virus or HIV.
The potential for a vaccine is a “benchmark” in the 30-year long battle against the devastating disease that has reaped havoc on communities of color worldwide. The vaccine was specifically designed for use in Thailand because it is based on the subtype B and E strains of HIV common there.
Thus, it isn’t clear whether it would work in Africa where subtypes, A, C and D predominate.
Two thirds of the 33 million people with HIV live in Africa, and 75% of all AIDS deaths in 2008 occurred there.
Of all racial and ethnic groups in the United States, HIV and AIDS have hit African-Americans the hardest. The reasons are not directly related to race or ethnicity, but rather to some of the barriers faced by many African-Americans including poverty (being poor), sexually transmitted diseases, and stigma (negative attitudes, beliefs, and actions directed at people living with HIV/AIDS or directed at people who do things that might put them at risk for the disease).
At the end of 2007 there were an estimated 1.7 million Americans living with HIV infection. Even though Blacks account for about 13% of the US population, they accounted for 51% of the 42, 655 (including children) new HIV/AIDS diagnoses in 34 states with long-term, confidential name based HIV reporting.
Details of the research will be presented at the AIDS vaccine conference in Paris next month.
|< Prev||Next >|